RED BANK, NJ–(Marketwire – Feb 7, 2012) – American CryoStem Corporation (OTCQB: CRYO) announced today that it has completed providing stem cell processing services for Personal Cell Sciences Corp., a cutting edge manufacturer of anti-aging skin care products.
The study involves researching the regenerative function of a conditioned medium obtained from each participant’s adipose (fat tissue) derived mesenchymal stem cells and their ability to promote the production or secretion of collagen, elastin and fibronectin related to skin wound healing.
John Arnone, CEO of American CryoStem and Founder of Personal Cell Sciences, commented, “CRYO’s patented tissue culture media and its proprietary, aseptic adipose tissue processing methodology allows, as an added benefit for PCS customers to store a clinical grade sample of their own stem cells for future use in regenerative medicine. We are pleased to provide comprehensive Bio-Insurance storage solutions at our clinical facility.”
The adipose tissue samples were acquired utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician’s office and sent to CRYO’s laboratory for processing. Once processed, the resulting stromal vascular fraction (SVF) was forwarded to the Personal Cell Sciences laboratory for proprietary formulation for patient specific products.
“We are very excited to announce our service agreement and participation in this clinical study for Personal Cell Sciences. This contractual manufacturing agreement reinforces our capabilities to provide CRYO’s exceptional clinical processing for relevant adult stem cell related products,” said Anthony Dudzinski, COO of American CryoStem. “We look forward to our continued business relationship with PCS and expanding these services to other developers to speed their product’s time to market.”
About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing products and services for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. CRYO’s clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.
For More Information, contact:
American CryoStem Corporation
188 East Bergen Place, Suite 204
Red Bank, NJ 07701